Core Insights - Shandong Gold has experienced a decline for five consecutive trading days, with a cumulative drop of -5.83% [1] - Shandong Gold Mining Co., Ltd. is a publicly listed company controlled by Shandong Gold Group, established in 2000 and listed on the Shanghai Stock Exchange in 2003, followed by a listing on the Hong Kong Stock Exchange in 2018 [1] - The company has expanded its capital market presence by also controlling Shanjin International Gold Co., Ltd., which is listed on the Shenzhen Stock Exchange [1] - In the second quarter of this year, China Europe Fund's China Europe Value Select Mixed A Fund entered the top ten shareholders of Shandong Gold, marking a new investment for the year [1] - The fund has achieved a year-to-date return of 16.26%, ranking 603 out of 2275 in its category [1] Fund Manager Profile - The fund manager of China Europe Value Select Mixed A is Yuan Weide, who has a master's degree and is a mid-generation fund manager at China Europe Fund [3][4] - Yuan Weide's research scope includes financial engineering, TMT (Technology, Media, and Telecommunications), new energy, technology, and consumer sectors [3][4] - He has a history of working as an industry researcher at Xinhua Fund Management Co., Ltd. from November 2011 to July 2015, and joined China Europe Fund in July 2015 [3][4]

Group 1 - China National Heavy Duty Truck Group Co., Ltd. (China National Heavy Duty Truck) has experienced a decline in stock price for four consecutive trading days, with a cumulative drop of -5.46% [1] - The company, established in 1956, is a pioneer in China's heavy-duty truck manufacturing, producing the first heavy-duty truck in China in 1960, which marked the end of the country's inability to manufacture heavy-duty vehicles [1] - In the second quarter of this year, China National Heavy Duty Truck's major shareholder, China Europe Fund's China Europe Dividend Enjoyment Mixed A Fund, increased its holdings [1] Group 2 - The China Europe Dividend Enjoyment Mixed A Fund has achieved a year-to-date return of 26.68%, ranking 201 out of 2105 in its category [1] - The fund manager, Lan Xiaokang, has a strong background in industry research and fund management, having worked in various financial institutions since 2011 [3][4] - The fund currently manages assets totaling 155.58 billion yuan, with a return of 140.40% during Lan Xiaokang's tenure [4]

Group 1 - The fund being offered is named "Zhongou Core Intelligent Mixed Securities Investment Fund" and is registered with the China Securities Regulatory Commission [1][14] - The fund has two classes of shares: Class A with code 025058 and Class C with code 025059 [2][14] - The fund's operation is contractual and open-ended, aiming to achieve investment returns that exceed its performance benchmark while controlling portfolio risk [15][14] Group 2 - The subscription period for the fund is from August 4, 2025, to August 15, 2025 [6][26] - The minimum total subscription amount for the fund is set at 200 million shares [55] - The fund is open to individual investors, institutional investors, qualified foreign investors, and other investors permitted by laws and regulations [18][14] Group 3 - The fund's investment range includes various financial instruments such as stocks, bonds, and derivatives, with a focus on maintaining liquidity [19][20] - The fund aims to invest 60%-95% of its assets in stocks and depositary receipts, with a maximum of 50% of stock assets in Hong Kong Stock Connect stocks [20] - The fund's initial share value is set at 1.00 RMB [17] Group 4 - The fund management fee consists of fixed management fees, contingent management fees, and excess management fees, which depend on the holding duration and annualized return of each share [14] - Investors must open a fund account with the company to subscribe to the fund, and existing account holders do not need to open a new account [9][39] - The fund's effective subscription funds will accrue interest during the subscription period, which will be converted into fund shares for the holders [10][38]

简历显示：葛兰女士:中国籍。美国西北大学生物医学工程专业博士。历任国金证券股份有限公司研究 所研究员,民生加银基金管理有限公司研究员。2014年10月加入中欧基金管理有限公司,曾任研究员、中 欧明睿新起点灵活配置混合型证券投资基金基金经理(2015年1月29日起至2016年4月22日)、中欧瑾泉灵 活配置混合型证券投资基金基金经理(2015年3月16日起至2016年4月22日)、中欧瑾源灵活配置混合型证 券投资基金基金经理(2015年3月31日起至2016年4月22日)、中欧瑾和灵活配置混合型证券投资基金基金 经理(2015年4月13日起至2016年4月22日)。现任中欧医疗健康混合型证券投资基金基金经理(自2016年9 月29日起至今),中欧明睿新起点混合型证券投资基金基金经理(自2018年7月12日起至今)、中欧阿尔法混 合型证券投资基金基金经理(2020年8月20日起至2023年9月28日)。 来源：金融界 金融界2025年7月25日消息，中欧医疗创新股票A(006228) 最新净值1.6496元，下跌2.19%。该基金近1个 月收益率19.35%，同类排名7|787；近6个月收益率62.55%，同类排 ...

首批21家机构入选网下专业机构投资者 "白名单" 智通财经7月25日电，中证协发布2024年网下专业机构投资者 "白名单"，共有首批21家网下专业机构投 资者纳入"白名单"。包括博时基金、大成基金、富国基金、广发基金、国泰基金、华安基金、华泰资 管、汇添富基金、交银施罗德基金、景顺长城基金、南方基金、平安资管、睿远基金、东方证券资管、 泰康资管、银华基金、招商基金、中金公司、人寿养老保险、中欧基金、中信证券。中证协将对纳 入"白名单"网下投资者采取激励措施，例如开通网下投资者注册绿色通道，供相关监管部门、自律组织 等在分类监管、自律管理等工作中参考使用。（智通财经记者 林坚） | | 2024年网下专业机构投资者"白名单" | | --- | --- | | 序号 | 网下投资者名称 | | 1 | 博时喜美最插掉限公司 | | 2 | 大成基金管理有限公司 | | 3 | 富国墓会管理有限公司 | | 4 | 广发基金管理有限公司 | | 5 | 国泰基金管理有限公司 | | 6 | 华安基金管理有限公司 | | 7 | 华泰资产管理有限公司 | | 8 | 汇添富基金管理股份有限公司 | | 9 | 交银 ...

Group 1: Company Overview - Sichuan Guoguang Agricultural Chemical Co., Ltd. has a technical service model that requires a significant number of terminal promotion personnel, leading to the recruitment of over 300 recent university graduates in 2025, primarily from agricultural colleges [3][4] - The company's technical marketing and service team exceeds 1,000 personnel [3] Group 2: Industry Landscape - The plant growth regulator industry consists of approximately 450 companies, with around 110 being registered pharmaceutical companies. As of the end of 2024, there are 1,734 registered certificates in China, with 33 companies holding 10 or more certificates, totaling 632 certificates [4] - The industry is characterized by small and dispersed enterprises, which is favorable for the development of leading companies [4] Group 3: Financial Performance and Shareholder Returns - The company approved a mid-term dividend plan for 2025 at the 2024 annual general meeting, aligning with the three-year shareholder return plan (2024-2026) [5] - The gross profit margin in Q1 2025 increased due to a higher sales volume of high-margin products and lower prices of some raw materials compared to the previous year [10] Group 4: Market Trends and Growth Potential - The plant growth regulator industry is expected to grow faster than the average growth rate of the pesticide industry, driven by the relatively recent application of these products in China and the presence of many untapped markets and crops [6] - The prices of raw materials required for the company's main plant growth regulator products have remained stable throughout the year [7] Group 5: Market Share Expansion Strategies - The company aims to enhance market share through continuous new product development, optimization of existing products, increasing the number of product registration certificates, and conducting field efficacy trials [8] - Quality management and supply capacity improvements are prioritized in production, while marketing strategies include matching technical service personnel with marketing plans and optimizing the distributor system [8]

Core Viewpoint - The transfer of 1% of shares by Shen Yougen, the actual controller of Dongfang Caifu, resulted in 17 well-known institutions acquiring a total of 158.8 million shares at a price of 21.66 yuan per share, amounting to a total of 3.44 billion yuan [2][4]. Group 1: Share Transfer Details - The share transfer involved 17 institutions, including prominent domestic and foreign entities such as E Fund, China Europe Fund, Guotai Junan Securities, and Morgan Stanley [2][3]. - The total number of shares transferred was 158.8 million, representing 1% of the company's total share capital [3]. - The transfer price was set at 21.66 yuan per share, which is a discount of 10.94% compared to the latest closing price of 24.32 yuan [4]. Group 2: Impact on Shareholding Structure - Prior to the transfer, Shen Yougen held 1.2% of the shares, which decreased to 0.19% post-transfer [3]. - The actual controller and their concerted actions held a combined 22.90% of the shares before the transfer, which will reduce to 21.89% after the transaction [4]. - The transfer will not change the control structure of the company or significantly impact its governance [3]. Group 3: Use of Proceeds and Strategic Implications - The funds raised from the share transfer will primarily be used for investments in technology startups [6]. - The introduction of high-quality long-term institutional investors is expected to enhance business cooperation and resource integration opportunities for Dongfang Caifu [7]. - The company is advancing its "AI + Finance" strategy, with ongoing development of its proprietary financial model to drive innovation and value creation in the financial ecosystem [6].

Company Overview - Bid Pharma, established in 2007 and headquartered in Shanghai, focuses on the research, production, sales, and custom synthesis of pharmaceutical intermediates [1] Stock Performance - Bid Pharma has experienced a decline in stock price for five consecutive trading days, with a cumulative drop of -3.54% [1] Fund Holdings - China Europe Fund's China Europe Medical Health Mixed A is among the top ten shareholders of Bid Pharma, maintaining its position in the second quarter of this year [2] - The fund has achieved a year-to-date return of 19.65%, ranking 909 out of 4513 in its category [2] Fund Performance Comparison - The performance of China Europe Medical Health Mixed A fund shows a year-to-date increase of 19.65%, compared to the category average of 13.49% and the CSI 300 index's 5.44% [3] Fund Manager Profiles - The fund is managed by Guo Lan, who has a Ph.D. in Biomedical Engineering from Northwestern University and has been with China Europe Fund since October 2014 [4][5] - Zhao Lei, who has a master's degree and previously worked as a researcher in the pharmaceutical and biotechnology sector, joined China Europe Fund in May 2021 and became a fund manager on July 4, 2025 [6] Fund Management Details - Guo Lan has managed multiple funds and has a total fund size of 399.08 billion with a return of 106.72% [5] - Zhao Lei currently manages two funds with a total size of 308.01 billion, achieving a return of 8.02% since her appointment [6] Company Structure - China Europe Fund Management Company was established in July 2006 and has 25 shareholders, with WP Asia Pacific Asset Management LLC holding 23.30% [6]

Group 1 - The core viewpoint is that Hong Kong's innovative drug concept stocks are becoming increasingly active, with significant gains in the net value of related ETFs [2] - As of July 18, the top ten passive index funds by weekly growth include various innovative drug ETFs, all showing over 13% increase [3] - The top-performing fund, Invesco Great Wall CSI Hong Kong Stock Connect Innovative Drug ETF Link A Fund, achieved a weekly growth of 13.98% [3] Group 2 - The Invesco Great Wall CSI Hong Kong Stock Connect Innovative Drug ETF Link Fund was established on March 14, 2025, with a net asset value of approximately 493 million yuan as of the end of Q2 [4] - The fund has underperformed its benchmark by 4.76 percentage points since inception but outperformed it by 3.69 percentage points in Q2 [4] - The only healthcare ETF among the top funds is the Fortune Heng Seng Hong Kong Stock Connect Healthcare ETF, which has underperformed its benchmark by 0.76 percentage points since inception and by 7.43 percentage points over the past year [5]

Group 1 - The net asset value of the China Europe Fund's China Europe CSI All-Share Healthcare Equipment and Services Index Fund A (021714) as of June 30, 2025, is 0.12 billion yuan, representing a decrease of 7.74% compared to the previous period [1] - The fund manager, Song Weiwei, has extensive experience and has held multiple managerial positions in various funds since 2024 [2] - Recent changes in fund share scale indicate a total share of 0.02 billion as of June 30, 2025, with a net asset change rate of -24.80% [3] Group 2 - The fund's performance shows a 3-month return of 7.22%, a 1-year return of 9.65%, and a cumulative return since inception of 9.65% [3] - The top ten stock holdings of the fund include Mindray Medical, United Imaging Healthcare, Aier Eye Hospital, and others, with a combined holding percentage of 42.08% [3] - China Europe Fund Management Co., Ltd. was established in July 2006, located in Shanghai, with a registered capital of 220 million yuan [3]